Research and Development of mAb114 for Ebola

This Special Notice from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response posted a redacted justification and approval for a sole source contract. The contract is for research and development of monoclonal antibody mAb114 to treat Ebola and was awarded non-competitively to Ridgeback Biotherapeutics LP.

The purpose of this Special Notice and sole source award is to further research and development of mAb114, which has demonstrated protective effects in multiple animal models of Ebola infection and has advanced to clinical testing in humans. Ridgeback Biotherapeutics LP is the only entity deemed responsible to meet the agency's requirements due to its unique qualifications and capabilities in developing mAb114 based on prior experience. No other contractors were considered eligible for this opportunity due to Ridgeback Biotherapeutics' established work in progressing mAb114 from animal testing towards use as an Ebola therapeutic for humans. The Special Notice provides transparency on a noncompetitive contract award justified by FAR 6.302-1 for there being only one responsible source able to satisfy the requirement when no other contractor is capable.